Human factor H (HufH), a key inhibitor of the alternative pathway of complement, binds to Neisseria gonorrhoeae and constitutes an important mechanism of human-specific complement evasion. The Cterminal domain 20 of HufH contains the binding site for sialylated gonococci. We exploited differences in amino acid sequences between human and non-binding chimpanzee fH domain 20 to create cross-species mutations to define amino acids important for binding to sialylated gonococci. We used fH/Fc fusion constructs that contained contiguous fH domains 18-20 fused to Fc fragments of murine IgG2a. The Fc region was used both as a tag for detection of each fusion molecule on the bacterial surface and as an indicator for complement-dependent killing. Arginine (R) 1203 was critical for binding to both porin (Por) B.1A and PorB.1B strains. Modeling of the R1203N human-to-chimpanzee mutation using the crystal structure of HufH19-20 as a template showed a loss of positive charge that protrudes at the C-terminus of domain 20. We tested the functional importance of R1203 by incubating sialylated gonococci with normal human serum, in the presence of wild-type HufH18-20/Fc or its R1203A mutant. Gonococci bound and were killed by wild-type HufH18-20/Fc but not by the R1203A mutant. A recombinant fH/Fc molecule that contained chimpanzee domain 20, humanized only at amino acid 1203 (N1203R) also bound to sialylated gonococci and restored killing. These findings provide further insights into the species-specificity of gonococcal infections and proof-of-concept of a novel therapeutic approach against gonorrhea, a disease rapidly becoming resistant to conventional antibiotics.
. PorB.1A gonococci frequently cause disseminated disease while PorB.1B strains usually cause local urogenital disease and pelvic inflammatory disease in women (8, 9) . Most gonococcal PorB.1A strains can bind fH and/or C4BP (hence they exhibit "stable" serum resistance), while PorB.1B strains bind fH weakly (5) unless their lipooligosaccharide (LOS) is sialylated (5, 10) . Some PorB.1B strains can bind C4BP independent of LOS sialylation (6) .
Factor H (fH) is an important fluid-phase alternative complement pathway inhibitor. It inhibits the assembly of an active C3 convertase by competing with factor B for C3b binding, accelerates the decay of the alternative pathway C3 convertase (C3bBb), and acts as a cofactor in factor I-mediated cleavage of C3b to iC3b (11) (12) (13) (14) (15) . FH is composed of 20 short consensus repeat (SCR) (also called complement control protein [CCP] ) domains (16) , each comprising ~60 amino acids (17) . The structural integrity of each domain is maintained by two disulfide bonds (18) .
Gonococcal LOS that contains lacto-Nneotetraose (LNT) (19) becomes sialylated when the bacteria are grown in media supplemented with 5′ -cytidinemonophospho-N-acetylneuraminic acid (CMP-NANA) (19, 20) . Sialylation of LOS also occurs in vivo (21) and renders those strains that are otherwise susceptible to complementmediated killing, resistant to killing by NHS (22) . This is termed "unstable" serum resistance, because it is a property that is lost when organisms are grown in media that lack CMP-NANA (23) . Sialylation of gonococci enhances their ability to bind human fH (HufH) (10) . The primary binding site for sialylated gonococci (both PorB.1A-and PorB.1B-expressing strains) resides in a region spanned by the three C-terminal fH domains, 18 through 20 (24) .
Natural infection with N. gonorrhoeae is restricted to humans. HufH, but not fH from other primates such as chimpanzee (Pan troglotydes) and rhesus macaque (Macaca mulatta), bind directly and strongly to gonococci (24) . In this study, we used fH/Fc fusion constructs that contained contiguous fH domains 18-20 from human (Hu) or chimpanzee (Ch), fused in frame at their C-terminal ends to the N-terminus of the Fc fragment of murine IgG2a, to examine the effects of amino acid mutations in fH domain 20 on the binding of fH to sialylated gonococci. The Fc region served as a tag for detection of each fusion molecule and also enabled complement-dependent bacterial killing. We exploited the differences in amino acid sequence between human and chimpanzee fH located in the C-terminal fH domains to define the amino acids that are important for binding of HufH to sialylated N. gonorrhoeae.
Experimental Procedures
Bacterial strains.
N. gonorrhoeae serotype PorB.1B strain F62 (25) and serotype PorB.1A strain 252 (5) have been described previously. Strain 252 was chosen in this case as an example of a PorB.1A strain that binds to HufH but fails to bind the classical complement pathway inhibitor, C4BP (5), thereby eliminating confounding by C4BP in bactericidal assays. Bacteria that had been grown on chocolate agar supplemented with Isovitalex ® equivalent (26) in 5% CO 2 for 10-12 h at 37°C were suspended in gonococcal liquid media (26) and grown to the mid-log phase. Sialylation of gonococcal LOS was achieved by adding CMP-NANA to a final concentration of 2 µg/ml to the growth media. Bacteria were washed and resuspended in Hanks' balanced salt solution (HBSS) containing 0.15 mM CaCl 2 and 1 mM MgCl 2 (HBSS ++ ) for use in binding assays. Escherichia coli (Invitrogen) used for site-directed mutagenesis were cultured in Luria Bertani (LB) broth or on LB agar.
Serum and complement reagents. Serum was obtained from seven normal healthy adult volunteers with no history of gonococcal infection who provided written informed consent. Participation was approved by the University of Massachusetts Medical School's Human Subjects/IRB, Office of Research. Sera were pooled and stored at -70°C. For some experiments, complement was inactivated by heating serum at 56°C for 30 min. HufH was purchased from Complement Technologies (Tyler, TX). Depletion of IgG and IgM from serum, testing for the adequacy of depletion and hemolytic activity of the depleted serum were all performed exactly as described previously (27) . Heparin, sodium salt (ICN Biomedicals) was isolated from porcine intestinal mucosa and has most chains in the range of 17,000-19,000 Da. Anti-thrombin-III activity was approximately 100 USP units/mg. The amount of heparin needed to prevent coagulation was between 20 and 50 unit/ml of whole blood.
Sequence comparison. Amino acid sequences of domains 18, 19 and 20 of human and chimpanzee factor H were obtained from the GenBank database (accession Nos. Y00716 and XP001136531, respectively) and were aligned using the BIOEDIT alignment program.
Recombinant fH fragment/Fc fusion proteins (fH/Fc
). FH/Fc fusion constructs were used to examine the effects of amino acid mutations in fH domain 20 on the binding of fH to sialylated gonococci. These constructs contained contiguous fH domains 18-20 from human (Hu) or chimpanzee (Ch), fused in frame at their Cterminal ends to the N-terminus of the Fc fragment of murine IgG2a (fH/Fc fusion proteins). The predicted amino acid sequence of the wild-type Hu18-20/Fc fusion protein is shown in Fig. S1 . Construction of these chimeric molecules and estimation of the concentration of the fH/Fc fusion proteins in concentrated cell culture supernatants have been described previously (24) . Briefly, Chinese hamster ovary cells were transfected with each of the fH/Fc constructs using lipofectin (Invitrogen), according to the manufacturer's instructions. Media from transfected cells were collected over a 2-day period, culture supernatants concentrated using Amicon Ultra (Millipore) and fH/Fc protein concentrations determined by ELISA. Recombinant proteins that were used in bactericidal assays were purified over HiTrap Protein A HP (GE Healthcare); their concentrations were determined by absorbance at 280 nm.
Site-directed mutagenesis of fH domain 20. To map the amino acids in HufH domain 20 and to assess systematically their importance for binding to sialylated N. gonorrhoeae, we created ten HufH18-20/Fc mutants by replacing one or two amino acid residues in domain 20 with the corresponding chimpanzee residue(s). A list of primers used to create the recombinant fH/Fc proteins and those used for site-directed mutagenesis are listed in Table S1 .
Single amino acid mutations were also generated in the reverse direction (chimpanzee-to- Modeling of HufH19-20 R1203N. The tertiary structure of fH19-20 protein with the R1203N mutation was generated by homology-based molecular modeling using the previously solved crystal structure of wild type fH19-20 as a template (31) . The generated structure was energy minimized using the Steepest descent algorithm in the Discover module of the Insight II software package (Accelrys Inc., San Diego).
Electrostatic potentials of the fH19-20 wildtype and the R1203N mutant structures were calculated after addition of hydrogens using the Adaptive Poisson-Boltzmann Solver (APBS) (32) that was run using the PyMOL version 1.3 graphic interface (Schrödinger, LLC, NY). The program PDB2PQR (33) was used to generate the PQR file required by APBS.
Serum bactericidal assay. Serum bactericidal assays were used to test whether fH/Fc fusion proteins that inhibited binding of full-length HufH to bacteria resulted in killing of gonococci by normal human serum (NHS). In certain experiments, IgG and IgM depleted NHS was used as a source of active complement. Serum bactericidal assays were performed as described previously (26) that also included the use heat inactivated serum as negative controls. Briefly, 2000 CFU of gonococci (sialylated) were incubated with purified fH/Fc fusion proteins at concentrations ranging from 0.5 to 33 µg/ml followed by the addition of 10% NHS (v/v). The final volume of reaction mixtures was 150 µl. Aliquots of 25 µl were immediately removed from reaction mixtures and plated in duplicate (t 0 ) and again after 30 min. of incubation at 37°C (t 30 ). Following overnight incubation of the plates at 37°C in 5% CO 2 , colonies were counted and the percent killing calculated as the ratio of the number of colonies at t 0 vs. the number at t 30 .
RESULTS

HufH domain 20 contains the binding site for sialylated N. gonorrhoeae.
Domains 18-20 of HufH contain the binding site for sialylated gonococci (24) . Our goal was to determine the amino acid(s) in these domains that contribute to human-specific binding of fH to sialylated gonococci. We used chimpanzee fH (ChfH), which does not bind to sialylated gonococci (24) , as a basis to compare the amino acid sequences in fH domains 18-20 and then substituted individual amino acids. As a prelude to the subsequent experiments in this study, we first ascertained that only HufH18-20/Fc, but not ChfH18-20/Fc, bound to each of the two sialylated strains of gonococci (Fig. 1A) . We also confirmed that HufH18-20/Fc, but not ChfH18-20/Fc, inhibited binding of full-length fH to sialylated gonococci in a dose-dependent manner ( Fig 1B) . The inhibition by HufH18-20/Fc was more efficient with the PorB.1B strain F62 than with the PorB1.A strain 252 (left panels , Fig.  1B) ; approximately 4-fold more HufH/18-20 was required to achieve similar levels of inhibition of binding to sialylated strain 252 compared to sialylated strain F62. Domain 18 of HufH and ChfH are identical and domain 19 differs by only two amino acids; in domain 20 there are a total of 11 amino acid differences between human and chimpanzee ( Fig. 2A) . Therefore, we speculated that the Cterminal domain 20 was likely to harbor the gonococcal binding site. This was confirmed using a fusion protein that contained HufH domains 18-19 and ChfH domain 20 fused to murine Fc (HufH18-19/ChfH20/Fc), which did not bind to sialylated PorB.1A or PorB.1B strains of N. gonorrhoeae (Fig. 1A) . Next we sought to define the amino acids in domain 20 that were important for HufH interactions with sialylated gonococci.
Arginine 1203 in domain 20 of HufH is critical for binding to sialylated N. gonorrhoeae.
The 11 amino acids in HufH domain 20 that are unique to humans were changed one at a time (in one instance 2 were simultaneously changed (T1184K/ Q1187E)) to the corresponding residues in ChfH domain 20 using site-directed mutagenesis ( Fig. 2A) . Ten HufH 18-20/Fc mutant proteins were constructed initially. Western blot analysis of the recombinant HufH18-20/Fc proteins in concentrated supernatants is shown in Fig. S2 . We compared HufH18-20/Fc mutant protein binding (using median fluorescence) to sialylated gonococci against wild type HufH18-20/Fc binding. Eight of the mutant proteins (N1176K, T1184K/Q1187E, L1189I, V1200I, S1209P, R1210S, T1213A or A1229V) bound to both sialylated PorB.1A and PorB.1B strains ≥50% relative to the wild type (Fig. 2B) . The R1203N mutation resulted in a significant decrease in binding to both strains (Fig. 2B) . Based on this observation, an additional mutant that substituted alanine instead of asparagine (R1203A), was used to verify that the observed effect of the R1203N mutation was not based on a conformational change in the region of the mutation (34) but rather that the residue R1203 itself was important for HufH binding to sialylated gonococci (Fig. 2B) . Similar to the R1203N mutant, binding of the R1203A mutant to sialylated gonococci was also decreased significantly ( Fig. 2B) suggesting that the R1203 residue played a key role in the interaction of HufH with sialylated gonococci. In addition, the T1217A mutant showed 36 and 18% binding to sialylated PorB.1A and PorB.1B respectively, relative to the binding of wt HufH18-20/Fc (Fig.  2B) .
Most gonococci express the lacto-Nneotetraose LOS species that becomes sialylated in vivo, the rationale behind the use of sialylated bacteria in these studies. In order to understand if LOS sialylation influenced the amino acid residues of fH18-20 that determined species-specificity of fH binding to N. gonorrhoeae, we compared the binding profiles of HufH18-20/Fc and its mutant proteins both to sialylated and unsialylated gonococci. While unsialylated PorB.1B strain F62 binds barely detectable amounts of HufH by FACS (35), PorB.1A strain 252 binds to HufH even in the unsialylated state (24) and therefore a comparison between sialylated and unsialylated bacteria was carried out using both forms of strain 252 only. As shown in Fig. S3 , binding of HufH18-20/Fc and its mutant proteins was similar, with the expected increases in levels of binding seen throughout when LOS was sialylated.
'Humanizing' chimpanzee domain 20 selectively at position 1203 restores fH binding to gonococci.
Having shown that R1203 was important for binding of HufH to sialylated gonococci, we next considered whether replacement of asparagine (N) 1203 in ChfH20 with arginine (R), the human counterpart, was sufficient to restore binding of fH to sialylated gonococci. This single substitution (HufH18-19/ChfH20 N1203R/Fc) was sufficient to enable binding of this construct to both sialylated gonococcal strains (Fig. 3) . Because the T1217 residue in HufH20 also appeared to be important in binding to gonococci (Fig. 2B) , we also examined whether binding of a mutant construct that possessed A1217T (called HufH18-19/ChfH20 A1217T/Fc) in the background of HufH18-19/ChfH20/Fc could restore binding to gonococci. As seen in Figure 3 , this mutant did not bind to the sialylated gonococcal strains.
Heparin inhibits binding of HufH18-20/Fc to sialylated gonococci.
Heparin is a highly sulfated negatively charged carbohydrate that is often used as a surrogate for host glycosaminoglycans (29, 30, 36) that bind fH in order to down-regulate complement activation on human cell surfaces (36, 37) . A heparin-binding site is located in domain 20 of fH (29, 30) . Consistent with the ionic nature of the heparin-HufH20 bond, positively charged residues such as R1182, R1203, R1206 and K1230 in HufH20 are involved in the interaction with heparin (31, 36, 38) . Because R1203 is involved in binding of fH to heparin (39, 40) as well as to sialylated gonococci, we hypothesized that heparin would inhibit binding of HufH to sialylated gonococci. Indeed, heparin inhibited the binding of HufH18-20/Fc to sialylated PorB.1A and PorB.1B strains of N. indicating that binding sites for heparin and sialylated gonococci in HufH domain 20 overlap.
Modeling of the R1203N mutant structure
Point mutations may affect structural integrity of a protein. However, it is unlikely that mutating the amino acids in HufH to their ChfH counterparts would destabilize the tertiary structure of the molecule. Because the R1203N mutation in HufH 18-20 abolished binding to gonococci, we modeled the effect of the mutation by homology-based molecular modeling of the R1203N mutant using the crystal structure of fH domains 19-20 (31) as a template. In the crystal structure the R1203 residue is exposed on the (31) . In the model it was apparent that the mutation, R1203N, resulted in a dramatic local change by removal of the positive charge on a protrusion that is formed by the side chain of the residue (Fig. 5A and B) . The side-chain of R1203 is directed away from cysteine 1201 (Fig. S4) ; mutating this residue to an alanine does not affect the integrity of the disulfide bond or the overall domain structure as evidenced by X-ray crystallography (41) .
The residue T1217 had also appeared to be involved in binding of HufH18-20 to N. gonorrhoeae (Fig. 2B ) but this finding was not corroborated by mutating the residues on ChfH to the corresponding human residues (Fig. 3) . Although the T1217 residue is surface exposed in the crystal structure of fH19-20 (Fig. 5B) , T1217 is located on the side surface of domain 20, approximately 24 Å from the R1203 residue.
Complement-dependent killing of sialylated gonococci by HufH18-20/Fc
The ability of HufH18-20/Fc to bind to sialylated gonococci at a location where fulllength fH binds (Fig. 1B) in combination with Fc's ability to activate the classical pathway of complement (Fig. S5 ) prompted us to investigate whether HufH 18-20/Fc and the derived HufH18-19/ChfH 20 N1203R/Fc mutant, which also bound to sialylated gonococcal strains F62 and 252, supported complement-dependent killing of N. gonorrhoeae. Adding HufH18-20/Fc to NHS resulted in killing of sialylated strain F62 (PorB.1B) in a dose-dependent manner (Fig. 6, left  panel) . Seventy two percent killing was seen at concentrations as low as 1 µg/ml. Adding HufH18-19/ChfH 20 N1203R/Fc to NHS showed similar results. As a control, we used HufH18-20 R1203A/Fc that did not bind to gonococci; as expected, addition of this mutant molecule did not diminish survival of the sialylated F62 strain, except at the highest concentration used (33.2 µg/ml yielded 15% killing). Sialylated PorB.1A strain 252 was killed 13% by complement in NHS in the presence of HufH18-20/Fc at concentrations (4.2 µg/ml; Fig. 6 
DISCUSSION
To survive the milieu of the genital tract and establish infection, N. gonorrhoeae must evade the innate immune system at this location. Naturally occurring antibodies and complement are important effector arms of the immune response in the lower genital tract, particularly in women (3). Gonococci have developed numerous mechanisms to evade complement-mediated killing in vivo; one such mechanism is sialylation of LNT LOS. Mechanisms of serum resistance conferred by gonococcal LNT LOS sialylation include decreased binding of antibodies (46) and enhanced binding of HufH (10) .
The ability of gonococci to bind HufH selectively may contribute an explanation of why gonorrhea occurs naturally only in humans (24) . HufH and ChfH domain 20 differ by 11 amino acid residues. Nine of these 11 amino acid residues (except V1200 and A1229) are surface exposed (31) . Although the other amino acids common to both human and chimpanzee fH are undoubtedly involved in the binding between fH and sialylated gonococci, we have shown that R1203 is an important residue that dictates the species-specificity of fH binding to sialylated gonococci. R1203N (or R1203A) mutations alone were sufficient to abrogate binding of fH to both sialylated PorB.1A and PorB.1B strains of N. gonorrhoeae. Complementing this observation, a chimpanzee-to-human mutation, N1203R, in ChfH domain 20 resulted in a gain of function-that is, binding to gonococci. Crystal data of HufH domains 19-20 (31) and our current modeling data of HufH20 with an R1203N mutation (Fig. 5) , indicates that this surface exposed positively charged residue located 29 amino acids upstream of the C-terminus of HufH is essential for binding to sialylated gonococci enabling organisms to evade complement-mediated killing. Our findings provide additional understanding of the molecular basis of human-specific binding of fH to sialylated gonococci.
Residue R1203 is a component of the heparin-binding site in HufH 20 (39, 40) and in accordance with these previous studies, the HufH18-20/Fc R1203N mutant showed decreased binding to heparin by ELISA when compared to HufH18-20/Fc (Fig. S7) . A model of the R1203N mutation shows that loss of a positive charge at this location disrupts a positively charged belt, which is presumed to be the heparin-binding site in HufH 20 (31, 36, 38) . In addition, heparin inhibited binding of HufH18-20/Fc (and fulllength HufH) to sialylated PorB.1A and PorB.1B gonococci, suggesting that the point(s) of contact between fH and sialylated gonococci overlap with the heparin binding site(s) in fH. The 1203 residue is also involved in the binding of factor H and complement C3b and C3d ( (47) and Fig. S8) .
In earlier studies we demonstrated that LOS sialic acid increases HufH binding to PorB.1B-bearing strains (10); subsequently we have also shown that gonococcal Por is essential for the interaction between HufH and sialylated PorB.1B-bearing gonococci (35) . However, it is possible that sialylated LOS, gonococcal Por and HufH form a ternary complex. It is noteworthy that subtle variations are seen in PorB.1A and PorB.1B interactions with recombinant HufH18-20/Fc mutants (Fig. 2B) . Variations observed in the interactions of the two PorB types with HufH18-20/Fc are not entirely unexpected because the predicted surface-exposed loop sequences of the two PorB molecules differ substantially (48) .
The mutation T1217A appeared to have had an effect on the binding of HufH to sialylated gonococci. However, the reverse mutation created in HufH18-19/ChfH20/Fc did not restore binding to sialylated gonococci. The structure of HufH19-20 (31) indicates that residue R1203 is on a different surface of the fH19-20 protein than the T1217 residue. While the location of the T1217 residue on the structure of FH19-20 does not exclude the possibility that it was involved in the interaction, it also possible that the T1217A mutation itself (independently) may have resulted in decreased binding efficiency between the recombinant (HufH18-20 T1217A/Fc) and sialylated gonococci due to, for example, (small) aliphatic changes at this site that might have resulted in diminished solubility of the recombinant protein and resultant diminished binding in the reaction mixtures (49, 50) . Failure to corroborate this finding when humanization of position 1217 in HufH18-19/ChfH20 A1217T/Fc did not result in enhanced binding as it had when position 1203 was humanized, suggests that residue T1217 is not directly involved in the interaction with gonococci.
In this study, we have shown that binding of HufH18-20/Fc to both PorB.1A and PorB.1B strains enabled complement-dependent killing of these gonococcal strains (Fig. 6) . Sialylated PorB.1B strain F62 was killed completely by HufH18-20/Fc at 2 µg/ml. However, sialylated PorB.1A strain 252 required a higher concentration of HufH18-20/Fc to kill it and complete killing of this strain by HufH18-20/Fc was not achieved by concentrations that exceeded by nearly 10-fold those required to kill sialylated PorB.1B strain F62. We have reported that sialylated PorB.1B strain F62 binds HufH via domains 18-20 exclusively, while PorB.1A strain 252 binds HufH via domains 18-20 and separately, by domain 6 (24, 51) . A proposed functional structure of fH suggests that monomeric HufH adopts a folded-back conformation (52) where domains, 12-14 contain the site of a bend or hinge (30) that increases proximity of SCR 6 and 20 domains to binding sites on N. gonorrhoeae. This may result in enhanced binding (and resultant function) of factor H. A requirement for engagement of fH via two closely spaced binding sites on this molecule for the sialylated PorB.1A strain might explain the inability of HufH18-20/Fc to completely kill this strain.
In conclusion, we have defined amino acids in human fH that are involved in binding on the surface of N. gonorrhoeae. Our strategy and findings may aid in the development of molecules that not only bind to gonococci but that also activate the classical pathway through the Fc at vulnerable sites on N. gonorrhoeae otherwise occupied by factor H. We acknowledge that such an approach will require further refinement of the molecule such that it binds only to the pathogen and not to eukaryotic cells to minimize damage to the host. This may provide novel therapeutic options against this pathogen that is rapidly becoming resistant to multiple antibiotics (53). In addition, a deeper molecular understanding of species-specific binding of fH to gonococci has been elucidated, which may shed additional light on the basis for the restriction of gonococcal infection to humans.
53.
Tapsall Abbreviations used in this paper: fH, factor H; HufH, human fH; NHS, normal human serum; Por, porin; LNT, lacto-N-neotetraose; LOS, lipo-oligosaccharide; CMP-NANA, 5′ -cytidinemonophospho-N-acetylneuraminic acid; ChfH, chimpanzee fH. 
